A5083501037- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Cancer Cells and Metastasis
- Immunotherapy and Immune Responses
- Advanced Breast Cancer Therapies
- Ovarian cancer diagnosis and treatment
- Immune cells in cancer
- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Single-cell and spatial transcriptomics
- COVID-19 and healthcare impacts
- Chemokine receptors and signaling
- Cancer Genomics and Diagnostics
- Cancer, Stress, Anesthesia, and Immune Response
- Systemic Sclerosis and Related Diseases
- Neuroendocrine Tumor Research Advances
- Neutropenia and Cancer Infections
- Digital Radiography and Breast Imaging
- Magnesium in Health and Disease
- Cognitive Science and Education Research
- Biosimilars and Bioanalytical Methods
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Neural and Behavioral Psychology Studies
Azienda Sanitaria Unità Locale di Reggio Emilia
2017-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2024
CTO Hospital
2017
University of Parma
2015
University of Padua
2011
University of Modena and Reggio Emilia
2010-2011
Azienda Unita' Sanitaria Locale Di Modena
2010
Neoadjuvant-chemotherapy (NAC) is considered the standard treatment for locally advanced breast carcinomas. Accurate assessment of disease response fundamental to increase chances successful breast-conserving surgery and avoid local recurrence. The purpose this study was compare contrast-enhanced spectral mammography (CESM) contrast-enhanced-MRI (MRI) in evaluation tumor NAC. This prospective approved by institutional review board written informed consent obtained. Fifty-four consenting...
BackgroundPrior exposure to adjuvant endocrine therapy (ET) and timing recurrence are crucial factors for first-line treatment choices in patients with hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancer (BC) clinical trial eligibility, classifying metastatic HR+/HER2− BC as sensitive (ES) or primary (1ER)/secondary (2ER) resistant. However, this classification is largely based on expert opinion no proper evidence exists date support its possible prognostic impact.MethodsThis...
The most common breast cancer (BC) susceptibility genes beyond BRCA1/2 are ATM and CHEK2. For the purpose of exploring clinicopathologic characteristics BC developed by or CHEK2 mutation carriers, we reviewed archive our Family Cancer Clinic. Since 2018, 1185 multi-gene panel tests have been performed. Nineteen 17 carriers affected 46 different BCs were identified. A high rate bilateral tumors was observed in (26.3%) (41.2%). While 64.3% luminal A-like, 56.2% B-like/HER2-negative. Moreover,...
Patients with triple-negative breast cancer (TNBC) achieving a pathological complete response (pCR) after neoadjuvant chemotherapy have better event-free survival. The role of gut microbiome in early TNBC is underexplored.Microbiome was analyzed by 16SrRNA sequencing.Twenty-five patients treated anthracycline/taxane-based were included. Fifty-six percent achieved pCR. Fecal samples collected before (t0), at 1 (t1), and 8 weeks (t2) from chemotherapy. Overall, 68/75 (90.7%) suitable for...
Abstract Neoadjuvant chemotherapy (NAC) alone or combined with target therapies represents the standard of care for localized triple-negative breast cancer (TNBC). However, only a fraction patients have response, necessitating better understanding complex elements in TNBC ecosystem that establish continuous and multidimensional interactions. Resolving such complexity requires new spatially-defined approaches. Here, we used spatial transcriptomics to investigate organization at diagnosis...
BackgroundIntermediate clinical endpoints (ICEs) are frequently used as primary endpoint in randomised trials (RCTs). We aim to assess whether changes different ICEs can be predict overall survival (OS) adjuvant breast cancer trials.MethodsIndividual patient level data from phase III RCTs conducted by the Gruppo Italiano Mammella (GIM) and Intergruppo (MIG) study groups were used. computed according STEEP criteria. Using a two-stage meta-analytic model, we assessed surrogacy of each ICE at...
This study aimed to evaluate contrast-enhanced mammography (CEM) accuracy and reproducibility in the detection measurement of residual tumor after neoadjuvant chemotherapy (NAC) breast cancer (BC) patients with calcifications, using surgical specimen pathology as reference. Pre- post-NAC CEM images 36 consecutive BC receiving NAC 2012–2020, calcifications bed at diagnosis, were retrospectively reviewed by two radiologists; described absence/presence size disease based on contrast enhancement...
The adoption of neoadjuvant chemotherapy (NACT) for breast cancer (BC) is increasing. need to repeat the biomarkers on a residual tumor after NACT still matter debate. We verified estrogen receptors (ER), progesterone (PR), Ki67 and human epidermal growth factor receptor 2 (HER2) status changes impact in retrospective monocentric series 265 BCs undergoing NACT. All changed with an overall tendency toward reduced expression. Changes PR were statistically significant (p = 0.001). 114/265...
e12649 Background: Systemic inflammatory markers derived from peripheral blood cells, such as the neutrophils and lymphocytes ratio (NLR), neutrophil lymphocyte (dNLR), platelet-lymphocyte (PLR), lymphocyte–monocyte (LMR), have shown promise prognostic markers. Currently, neoadjuvant treatment (NACT) for early triple-negative breast cancer (eTNBC) involves addition of an immune therapy, little is known about variation these in this specific context. Methods: This study evaluated two groups...
Here we describe a 77-year-old man with solitary fibrous tumor of the pleura showing increasing tracer uptake at 68Ga-DOTATOC PET/CT, demonstrating that may overexpress somatostatin receptors, therefore mimicking neuroendocrine tumors receptor PET/CT.
e14156 Background: Checkpoint inhibitors in cancer therapy have shown survival benefits the treatment of several ATs. However, risk serious side effects seems greater certain types tumors presenting reduced compliance with therapy. The aim this study is to evaluate safety profile and clinical IT, as appraised using clinically related biomarkers pts outside trials. Methods: In retrospective study, data were evaluated on Reggio Emilia Provincial Oncology Network who treated for ATs Nivolumab,...
Previous research involving epithelial ovarian cancer patients showed that, compared to germline BRCA (gBRCA) mutations, somatic (sBRCA) mutations present a similar positive impact with regard overall survival (OS) and platinum PARP (poly (ADP-ribose) polymerase) inhibitor sensitivity. Nevertheless, molecular testing in these studies did not include copy number variation (CNV) analyses of genes. The aim this study was explore the prognostic predictive role sBRCA as gBRCA who were also tested...
Background: Increasing evidences support a correlation between magnesium (Mg) homeostasis and colorectal cancer (CRC). Nevertheless, the role of Mg its transporters as diagnostic markers in CRC is still matter debate. In this study we combined X-ray Fluorescence Microscopy databases information to investigate possible imbalance CRC. Methods: tissue samples their non-tumoural counterpart from four patients were collected analysed for total level distribution by X-Ray Microscopy. We also...
Abstract Introduction Cardiovascular diseases (CVD) and Cancer (C), the most important causes of mortality worldwide. share many risk factors common pathophysiological processes such as chronic inflammation unfavorable cardio–metabolic profile. Progress in oncological treatments improved survival patients (Pt) but have increased likelihood short– long–term CV cardiovascular complications. The multidisciplinary collaboration between cardiologist onco–hematologists is task Cardioncology, an...
Systemic Sclerosis (SSc) is a chronic disease associated with 1.5-fold increase in cancer risk, including lung cancer, hematological malignancies, and breast (BC). This retrospective study aiming to explore the clinical pathological features of BC developed by SSc patients. A total 54.5% patients before (median interval: 5 years), whereas 45.5% after delay: 8 years). 93.1% were diagnosed an early stage tumor. Among invasive carcinomas, 70.8% presented low Mib1, 8.3% tubular histotype, 42.8%...
<p>Supplementary Figure 2. CD3 and CD20 expression analysis in AOIs comparing pCR pNR patients</p>